Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr;133(4):722-731.
doi: 10.1002/lary.30306. Epub 2022 Jul 15.

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta-Analysis

Jonathan C Pang  1 , Milind Vasudev  1 , Amy T Du  1 , Madeline M Nottoli  1 , Katherine Dang  1 , Edward C Kuan  1
Affiliations
Meta-Analysis

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta-Analysis

Jonathan C Pang et al. Laryngoscope. 2023 Apr.

Abstract

Objective: Topical intranasal anticholinergics are commonly prescribed for the relief of chronic rhinitis and associated symptoms, warranting thorough assessment of the supporting evidence. The present study aimed to evaluate the safety and efficacy of anticholinergic nasal sprays in the management of allergic and non-allergic rhinitis symptom severity and duration.

Methods: A search encompassing the Cochrane Library, PubMed/MEDLINE, and Scopus databases was conducted. Primary studies describing rhinorrhea, nasal congestion, and/or postnasal drip outcomes in rhinitis patients treated with an anticholinergic spray were included for review.

Results: The search yielded 1,029 unique abstracts, of which 12 studies (n = 2,024) met inclusion criteria for qualitative synthesis and 9 (n = 1,920) for meta-analysis. Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic. Compared to placebo, anticholinergic treatment was demonstrated to significantly reduce rhinorrhea severity scores (standardized mean difference [95% CI] = -0.77 [-1.20, -0.35]; -0.43 [-0.72, -0.13]) and duration (-0.62 [-0.95, -0.30]; -0.29 [-0.47, -0.10]) in allergic and non-allergic rhinitis patients respectively. Benefit was less consistent for nasal congestion, postnasal drip, and sneezing symptoms. Reported adverse effects included nasal mucosa dryness or irritation, epistaxis, headaches, and pharyngitis, though comparison to placebo found significantly greater risk for epistaxis only (risk ratio [95% CI] = 2.19 [1.22, 3.93]).

Conclusion: Albeit treating other symptoms with less benefit, anticholinergic nasal sprays appear to be safe and efficacious in reducing rhinorrhea severity and duration in both rhinitis etiologies. This evidence supports their continued use in the treatment of rhinitis-associated rhinorrhea.

Level of evidence: 1 Laryngoscope, 133:722-731, 2023.

Keywords: anticholinergic; meta-analysis; rhinitis; rhinorrhea; systematic review.

PubMed Disclaimer

References

BIBLIOGRAPHY

    1. Greiwe JC, Bernstein JA. Allergic and mixed rhinitis: diagnosis and natural evolution. J Clin Med. 2019;8(11):E2019. https://doi.org/10.3390/jcm8112019.
    1. Philpott C, Ta NH, Hopkins C, et al. Socioeconomic, comorbidity, lifestyle, and quality of life comparisons between chronic rhinosinusitis phenotypes. Laryngoscope. 2021;131(10):2179-2186. https://doi.org/10.1002/lary.29527.
    1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. https://doi.org/10.1111/j.1398-9995.2007.01620.x.
    1. Scarupa MD, Kaliner MA. Nonallergic rhinitis, with a focus on vasomotor rhinitis: clinical importance, differential diagnosis, and effective treatment recommendations. World Allergy Organ J. 2009;2(3):20-25. https://doi.org/10.1097/WOX.0b013e3181990aac.
    1. Leader P, Geiger Z. Vasomotor rhinitis. StatPearls. StatPearls Publishing; 2021. Accessed December 29, 2021. http://www.ncbi.nlm.nih.gov/books/NBK547704/.

LinkOut - more resources